Theravance Biopharma Q1 net loss $13.6M; YUPELRI sales up 6% to $58.3M

Theravance Biopharma, Inc.

2025-Q1 EPS reported -$0.27 revenue$15,388,000

YUPELRI net sales of $58.3M recognized by Viatris, up 6% vs Q1 2024; Theravance's implied 35% share $20.4M.
Net loss $13.6M vs $11.7M in Q1 2024; Non-GAAP net loss from ops $8.6M vs $4.5M.
Revenue $15.4M entirely from Viatris collaboration, up 6% YoY.
Cash $131M, no debt; reaffirming all financial guidance.
CYPRESS study open label enrollment nearing completion, final patient expected by late summer; top-line data ~6 months later.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.